Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03720431 | TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer | unknown | Phase 1 | 11 | PharmAbcineINDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03945604 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | completed | Phase 1 | 32 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03805399 |
| FUSCC Refractory TNBC Umbrella (FUTURE)(FUTURE) |
| unknown |
| Phase 1 / Phase 2 |
| 140 |
| Fudan UniversityOTHER |
| 1 |
| Aug 10, 2022 |
| clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | terminated | Phase 2 / Phase 3 | 27 | ERYtech PharmaINDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT04297267 | A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy(nonpCR GP) | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 0 | Jul 18, 2022 | clinicaltrials |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT02120469 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04395508 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05429294 | Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 | unknown | Phase 2 | 209 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT04105582 | Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells | completed | Phase 1 | 5 | Universidad Nacional de ColombiaOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT01276899 | Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | completed | — | 80 | Jewish General HospitalOTHER | 2 | Jun 2, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT03123211 | Expanded Access to Veliparib | no longer available | — | — | AbbVieINDUSTRY | 0 | May 24, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery(0927GCC) | terminated | Phase 2 | 5 | University of Maryland, BaltimoreOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04605575 | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 208 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | unknown | Phase 2 | 100 | Xijing HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346861 | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | unknown | Phase 3 | 240 | Fudan UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | terminated | Phase 2 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04192903 | Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04634747 | Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer | unknown | Phase 2 | 53 | OncoPep, Inc.INDUSTRY | 0 | Apr 20, 2022 | clinicaltrials |
| NCT04745975 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05334810 | DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer | unknown | Phase 2 | 191 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 19, 2022 | clinicaltrials |
| NCT04457700 | CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC | unknown | — | 218 | Peking UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
| NCT05288127 | Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature | unknown | Phase 2 | 55 | University of MalayaOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03145961 | A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients(c-TRAK-TN) | unknown | Phase 2 | 208 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.(REVER) | terminated | N/A | 4 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2022source: clinicaltrials